Literature DB >> 20207211

Merkel cell carcinoma: our experience with seven patients in Korea and a literature review.

Kyong-Je Woo1, Yoon-La Choi, Hun Soon Jung, Gyeongseo Jung, Young Kee Shin, Kee-Taek Jang, Joungho Han, Jai-Kyong Pyon.   

Abstract

BACKGROUND: Merkel cell carcinoma (MCC) is a rare but malignant cutaneous neuroendocrine carcinoma. As MCC has primarily been reported in Caucasians, MCC cases in Korea have not yet been reported. The purpose of this study was to retrospectively review our experience with the surgical treatment of MCC in Korea and to study its management and outcome.
METHOD: We retrospectively reviewed seven MCC case files between 2000 and 2008 from a single institution. We analysed patient characteristics, tumour location and size, staging, treatment methods and outcomes. We performed polymerase chain reaction (PCR) to detect Merkel cell polyomavirus (MCPyV) from formalin-fixed paraffin-embedded tissue specimens.
RESULTS: Two patients had stage I tumours, four patients had stage II tumours and one patient had a stage III tumour. Wide local excision with a clear resection margin was the primary modality of treatment in all cases. Adjuvant radiotherapy and chemotherapy were performed for selected patients. Recurrence was observed in two out of the seven cases during the follow-up period. MCPyV was detected by PCR in all seven cases.
CONCLUSION: MCC is an aggressive skin cancer, and pathologic lymph node evaluation is important for staging. Wide excision is the primary modality of treatment, but adjuvant radiotherapy could be positively considered if the tumour is large and the lesion is not confined to the dermis. MCPyV was detected by PCR in all cases, which suggests that MCPyV is also a putative aetiological agent in the carcinogenesis of MCC in Korea.
Copyright © 2010 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20207211     DOI: 10.1016/j.bjps.2010.01.020

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  9 in total

1.  Clinicopathologic features and prognostic factors of malignant eyelid tumors.

Authors:  Chang-Jun Wang; Hui-Na Zhang; Han Wu; Xin Shi; Jia-Jun Xie; Jin-Jing He; Koung-Hoon Kook; Sang-Yeul Lee; Juan Ye
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

2.  P53 mutation is a rare event in Merkel cell carcinoma of the head and neck.

Authors:  Claudia Lill; Sven Schneider; Chike B Item; Robert Loewe; Roland Houben; Daniel Halbauer; Gregor Heiduschka; Markus Brunner; Dietmar Thurnher
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-02-18       Impact factor: 2.503

3.  The clinical profile of Merkel cell carcinoma in mainland China.

Authors:  Philip I Song; Hao Liang; Wen-Qiang Wei; Yi-Qun Jiang; Jennifer S Smith; You-Lin Qiao
Journal:  Int J Dermatol       Date:  2012-09       Impact factor: 2.736

4.  Expression of β-catenin and cyclin D1 in Merkel cell carcinomas of the head and neck.

Authors:  Claudia Lill; Sven Schneider; Bahil Ghanim; Markus Brunner; Gregor Heiduschka; Robert Loewe; Dietmar Thurnher
Journal:  Wien Klin Wochenschr       Date:  2013-08-09       Impact factor: 1.704

5.  Quantitative analysis of viral load per haploid genome revealed the different biological features of Merkel cell polyomavirus infection in skin tumor.

Authors:  Satoshi Ota; Shumpei Ishikawa; Yutaka Takazawa; Akiteru Goto; Takeshi Fujii; Ken-ichi Ohashi; Masashi Fukayama
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

6.  Merkel cell carcinoma: A series of seven cases.

Authors:  Yong Woo Lee; Yong Chan Bae; Su Bong Nam; Seong Hwan Bae; Hoon-Soo Kim
Journal:  Arch Plast Surg       Date:  2019-09-15

7.  Merkel cell carcinoma in immunosuppressed patients.

Authors:  Janice E Ma; Jerry D Brewer
Journal:  Cancers (Basel)       Date:  2014-06-27       Impact factor: 6.639

8.  Merkel cell carcinoma in Taiwan: A series of 24 cases and literature review.

Authors:  John Wen-Cheng Chang; Yao-Yu Chang; Yen-Lin Huang; Yun-Feng Lo; Tsung-Ying Ho; Yi-Ting Huang; Huan-Wu Chen; Chun-Nan Yeh; Chiao-En Wu
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

9.  A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan.

Authors:  Wen-Cheng Chang; Amy Y Lin; Jason C Hsu; Chiao-En Wu; Connie Goh; Patrick Chou; Kaitlin Kuo; Anne Chang; Roberto Palencia
Journal:  Cancer Rep (Hoboken)       Date:  2021-05-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.